NCT03198078View on ClinicalTrials.gov

Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia

PHASE3CompletedINTERVENTIONAL

Enrollment

316

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

April 3, 2023

Study Completion Date

April 3, 2023

Conditions

Schizophrenia

Interventions

DRUG

Brexpiprazole (OPC-34712)

Once-daily, tablets

DRUG

Aripiprazole

Once-daily, tablets

DRUG

Placebo

Once-daily, tablets

Trial Locations (1)

73116

For additional information regarding sites, contact 844-687-8522, Oklahoma City

All Listed Sponsors

collaborator

H. Lundbeck A/S

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT03198078 - Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia | Biotech Hunter | Biotech Hunter